Institute suggests governments pay for Canadians to seek treatment abroad.
Lack of awareness continues to hinder use of group benefit programs.
Biosimilars Canada, a national association for the biosimilar medicines industry, is drawing attention to the recent imp
Insurers are already receiving numerous claims for a new appetite-suppressing drug.
Comorbidities and the outlook for treatment and recovery examined in new note.
New report and recommendations to form the basis of a pan-Canadian strategy.
The stampede for weight loss solutions already causing shortages for some diabetes patients and significant, unexpected